| Literature DB >> 27469140 |
Abstract
This study aimed to explore the neuroprotection and mechanism of isoflurane on rats with spinal cord ischemic injury. Total 40 adult male Sprague-Dawley rats were divided into the four groups (n=10). Group A was sham-operation group; group B was ischemia group; group C was isoflurane preconditioning group; group D was isoflurane preconditioning followed by ischemia treatment group. Then the expressions of TWIK-related K⁺ channel 1 (TREK1) in the four groups were detected by immunofluorescent assay, real time-polymerase chain reactions (RT-PCR) and western blot. The primary neurons of rats were isolated and cultured under normal and hypoxic conditions. Besides, the neurons under two conditions were transfected with green fluorescent protein (GFP)-TREK1 and lentivirual to overexpress and silence TREK1. Additionally, the neurons were treated with isoflurane or not. Then caspase-3 activity and cell cycle of neurons under normal and hypoxic conditions were detected. Furthermore, nicotinamide adenine dinucleotide hydrate (NADH) was detected using NAD+/NADH quantification colorimetric kit. Results showed that the mRNA and protein expressions of TREK1 increased significantly in group C and D. In neurons, when TREK1 silenced, isoflurane treatment improved the caspase-3 activity. In hypoxic condition, the caspase-3 activity and sub-G1 cell percentage significantly increased, however, when TREK1 overexpressed the caspase-3 activity and sub-G1 cell percentage decreased significantly. Furthermore, both isoflurane treatment and overexpression of TREK1 significantly decreased NADH. In conclusion, isoflurane-induced neuroprotection in spinal cord ischemic injury may be associated with the up-regulation of TREK1.Entities:
Keywords: Caspase-3; Isoflurane; NADH; Spinal cord ischemic injury; TREK1
Year: 2016 PMID: 27469140 PMCID: PMC5012874 DOI: 10.4062/biomolther.2015.206
Source DB: PubMed Journal: Biomol Ther (Seoul) ISSN: 1976-9148 Impact factor: 4.634
Fig. 1.Expression of TREK1 in four groups detected by immunofluorescent assay (A), real time-polymerase chain reactions (B) and western blot (C). Group A: sham-operation group; group B: ischemia group; group C: isoflurane preconditioning group; group D: isoflurane preconditioning plus ischemia treatment group. Data were presented as mean ± standard deviation (*p<0.05).
Fig. 2.Interfering efficiency of TREK1 in neurons. Data were presented as mean ± standard deviation (*p<0.05).
Fig. 3.PARP cleavage (A) and caspase-3 activity (B) when TREK1 was interfered with si-TREK1 in neurons. Data were presented as mean ± standard deviation (*p<0.05).
Fig. 4.Caspase-3 activity (A) of neurons and percentage of sub-G1 cells (B) when TREK1 was transfected (GFP-TREK1) or interfered (si-TREK1) under normal and hypoxic conditions. Data were presented as mean ± standard deviation (*p<0.05).
Fig. 5.NADH assay when TREK1 was transfected (GFP-TREK1) (A), and neurons were preconditioned with isoflurane (B). Data were presented as mean ± standard deviation (*p<0.05).